On December 6, 2023 Starpharma (ASX: SPL, OTCQX: SPHRY) reported that it is presenting at the Targeted Radiopharmaceuticals Summit Europe, having been invited to present at the specialist radiotheranostics conference being held in Berlin, Germany, from 5 to 7 December 2023 (Press release, Starpharma, DEC 6, 2023, View Source;mc_eid=bf52dd3418 [SID1234638169]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Targeted Radiopharmaceuticals Summit also includes speakers from Novartis, Bayer, Bicycle Therapeutics, AstraZeneca, Bristol-Myers Squibb, Precirix, Telix, and Fusion Pharmaceuticals. The Summit brings together professionals to provide insights into the research, development, and commercialisation of radiopharmaceuticals, including novel targets and combination therapies.
Starpharma’s Vice President of Development and Regulatory Affairs, Dr Jeremy Paull, will deliver a presentation on the application of Starpharma’s DEP platform for precision cancer radiotheranostics, including:
the application, versatility, and benefits of the DEP platform for targeted delivery of radiotheranostics; and
an overview of Starpharma’s two DEP HER2-targeted radiotheranostic products, DEP HER2-zirconium and DEP HER2-lutetium.
Starpharma recently reported data on DEP HER2-zirconium, a HER2-targeted radiodiagnostic candidate, demonstrating excellent tumour accumulation, a favourable biodistribution profile, with excellent imaging contrast between tumour and normal tissues, as well as rapid uptake in a HER+ breast cancer model. Starpharma’s radiotherapeutic product, DEP HER2-lutetium, has shown excellent anticancer activity, outperforming Herceptin labelled with lutetium, in a human breast cancer model. These products are designed to assist in improving the diagnosis, staging, monitoring, and treatment of HER2+ cancers, which include breast and upper gastro-intestinal cancers. The data reported in the presentation have been generated from studies conducted in collaboration with the Monash Institute of Pharmaceutical Sciences (MIPS) and the University of Queensland.
The conference presentation, ‘Branching Out: DEP Dendrimer Nanoparticles as a Versatile Platform for Precision Cancer Radiotheranostics’, will take place on 6 December 2023 in Berlin as part of the Novel Targets stream.